NCT06182579View on ClinicalTrials.gov

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 22, 2024

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions
Advanced Solid TumorIntratumoral Injection
Interventions
DRUG

RiMO-401

• Single intratumoral injection of RiMO-401 followed by palliative radiotherapy

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago

Sponsors
All Listed Sponsors
lead

Coordination Pharmaceuticals, Inc.

INDUSTRY